Biotech · Public company · Cambridge, MA, US

Black Diamond Therapeutics, Inc.

Ticker BDTX · SEC CIK 0001701541

Track this companyFree. Adds Black Diamond Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials32 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

silevertinib (BDTX-1535) monotherapyPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
silevertinib in combination with temozolomidePhase 2 · Glioblastoma (GBM)ClinicalTrials.gov · fetched Nov 12, 2026
temozolomide (TMZ)Phase 2 · Glioblastoma (GBM)ClinicalTrials.gov · fetched Nov 12, 2026
BDTX-189Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIPHASE2 · RECRUITING · started May 5, 2026ClinicalTrials.gov NCT07326566 · fetched Nov 12, 2026
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 31, 2022ClinicalTrials.gov NCT05256290 · fetched Nov 12, 2026
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.PHASE1 · TERMINATED · started Dec 19, 2019ClinicalTrials.gov NCT04209465 · fetched Nov 12, 2026